Ashraf Allam is the Regional Vice President of Mundipharma Middle East, Turkey and Africa region, based in Dubai, UAE.
Mundipharma is the leading US, research and manufacturing privately held, pharmaceutical company with annual revenues ~$5.0 Billions
In his current role Ashraf manages Mundipharma business in the countries across META region and is fully accountable for its profit and loss. He has been elected twice and served two terms as the Chairman, Executive Committee for the Association of American, European and Japanese research based manufacturing pharmaceutical and biotechnology companies (PhRMA) in the Middle East and Arica region.
Prior to joining Mundipharma in late 2013, Ashraf was appointed by Amgen; the world's largest Biopharmaceuticals Company. In 2006 Ashraf moved to Dubai to establish Amgen's operation in the Middle East, Turkey and Africa region which in few years became one the leading, top companies in the region. Before that he was based in Switzerland, where at Amgen’s International Headquarter he served as Vice President for International Business Development in addition to full profit and loss responsibility for the European markets of Italy, Greece and the Balkans. He was also in charge of the Corporate Development division focusing on growth, diversification and globalization of Amgen's business and was one of the key executive in the Global Strategy and Commercial Development Executive Team.
From 2001 to 2004 Ashraf worked in Johnson & Johnson in the capacity of Managing Director and was responsible for managing and leading the group’s umbrella of diversified companies based in Cairo.
Prior to that, he worked for Eli Lilly & Company in a variety of general management, sales, marketing, management development and business development roles in the US, Europe and the Middle East. He was also the Director of Global Economic Affairs and Pricing based in Indiana, USA, having previously been based in Geneva, Switzerland as Head of Area Sales and Marketing Operations for Central Eastern Europe and Middle East, Africa.
Faisal Bin Dail is the Chairman of the National Committee for Pharmaceutical Industries (NCPI) in Saudi Arabia, NCPI is the leading association for pharmaceutical manufacturers appointed in this position in March ,2018.
Faisal’s main task is to make sure that NCPI is on the track to meet its objectives and goals of providing patients with the best quality of medicine that is safe, effective and affordable. He has been active in the pharmaceutical industry for almost 20 years, started his career at MSD, and now he is the Deputy General Manager at AJA Pharmaceutical Industries Co. (AJA Pharma) which is a subsidiary of Saudi Chemical a leading joint stock company. AJA Pharma enjoys many partnerships with many global pharma companies in Licensing, Contract Manufacturing, and other collaboration forms.
Faisal BinDail has a degree in Pharmacy and MBA from King Saud University, and working with different stakeholders in Saudi Arabia to further develop & strengthen the pharma sector in Saudi Arabia.
Dr. Janet Byaruhanga is a qualified medical doctor and public health expert that obtained her postgraduate diploma in public health research from the University of Edinburgh and has over 12 years of experience in international development with special focus in human and social sectors. Served as health policy officer at the African Union Commission since 2007 where she provided technical leadership and oversight in development and delivery of key strategic continental policy frameworks, programmes and initiatives geared towards strengthening the continent’s healthcare delivery system, food security and nutrition, and promoting the social well-being and rights of women and children. Dr. Byaruhanga since 1st September 2017 joined the NEPAD Agency as a Senior Programme Officer-Public health. She is in charge of coordinating and facilitating development and implementation of policies on health and medical products and ensuring their alignment with industrial development; trade; science, technology and innovation polices in advancement of the African Union’s African Health Strategy and the Pharmaceutical Manufacturing Plan for Africa (PMPA).
Ahmed Faiyaz is strategy professional with 15 years’ experience and over 10 years’ experience in health sector transformation, investments, strategy planning, corporatization and privatization initiatives. He is currently the Advisor for Health Investments & PPP’s in Dubai Health Authority.
Dr. Awad Gabr has extensive business and industry experiences within the Pharma sector for more than 35 years by managing several well-known domestic and regional public and private companies (Sedico Pharmaceuticals, Kahira Pharmaceutical – EIMC United Pharmaceuticals – International Drug Industries – Saudi Import Company - Arabian Medical and Pharmaceutical Corporation)
Dr. Awad was appointed in setting up the sector strategic action plan and promotional activities by heading the sector Export Council under the ministry of Trade and Industry, with the objective of promoting the sector’s image and penetrate new markets.
He is a Board member and Treasurer of the Egyptian Pharmaceutical Manufacturer association and was a Board member and treasurer of the Pharmaceutical importers and distributors association.
Tariq has been in the Middle East for over 14 years, during which, he has seen the evolution from traditional to richer digital experiences. As a Director at Du in 2005, working closely with Apple, Samsung and Nokia, he was able to realize the part technology would play in this and went on to establish his own consultancy, helping agency clients develop digital content for AR, VR and MR. In 2015, he launched a lifestyle app with over 50000 users to better understand trends and behaviors which led him to where he is today, with a mission to transform health and wellness.
Malek El Husseini serve since Jun. 2017 as CEO of Byrne medical a leasing company. He served as Healthcare Operating partner at Qatar first Bank from Mar. 2016 till Jun. 2017. He was the GM, Diagnostic Cardiology for GE Healthcare from Sept. 2012 till Feb. 2016. Malek initially began working with GE Healthcare as Manager for Consulting Arm in 2006. In 2009 Malek was appointed the Business Development Director and handled the healthcare investment portfolio for GE Healthcare. Malek brings more than 24 years of industry experience, with over 12 years directly related to consulting in healthcare.
Since joining West in 2005 Christa has become an expert in Prefillable Systems and Delivery Technology in the Technical Customer Service and Marketing Departments. She has 20 years’ experience within the pharmaceutical industry, working in Quality in sterile filling, packaging and syringe manufacturing. She has been in her current position in West since 2016.
Christa holds a Diploma in Biomedical Engineering from the University of Aachen, Germany.
Dominique Joubert, former research director at the National Institute of Health and Medical Research in France, is a cofounder of ECS Screening and in charge of the scientific strategy of the company. She has been working on cancer since the beginning of her career, trying to understand how signalling pathways are altered in the tumor cell. She has demonstrated in particular the major potential of progastrin as a new target and new biomarker for cancer patients, allowing the development of two tools : a humanized monoclonal antibody that neutralizes progastrin oncogenic properties and a kit, CancerRead, for blood progastrin detection.
Yacine acted as Regulatory Evaluator of drugs registration dossiers, and as Permanent Secretary of the Economic Inter-Ministerial Committee in charge of Drugs Pricing at the General Directorate of Pharmacy and Health Equipment - Ministry of Health. He is President of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, Second Secretary of the Algerian Society of Pharmacy, and Regulatory Advisor to Algeria’s Ministry of Health.
Yacine actually holds the position of Assistant General Director in charge of Vaccines & Sera Development Projects at Pasteur Institute of Algeria, a public organization involved with R&D in the field of infectious, immune and neglected diseases. He is Expert Member of the National Immunization Technical Advisory Committee.
Yacine has been a Trainer in Regulatory Affairs, Keynote Speaker and Panelist across various healthcare regional and international congresses.
Yacine is also Associate Professor in Pharmaceutical Analytical Chemistry and Scientific Board Member at Medical Sciences Faculty of Algiers.
Professor Jaakko Tuomilehto qualified as MD in 1973 and MA and PhD in 1975. He is currently working as the Chief Scientific Officer at Dasman Diabetes Institute in Kuwait. He is Professor Emeritus of Public Health of the University of Helsinki, Finland. He initiated the Finnish Diabetes Prevention Study (DPS) that demonstrated a 58% reduction in incidence type 2 diabetes (T2D) with lifestyle intervention. He developed a simple, non-laboratory T2D risk score (FINDRISC) that has been used globally. He has published over 1700 articles, and is one of the most cited researchers with h-index 163.
Marwan Abdulaziz Janahi is Managing Director of Dubai Science Park, a vibrant and holistic science-focused community dedicated to serving entrepreneurs, SMEs and multinational enterprises operating in the life sciences, energy and environment sectors. Dubai Science Park is a member of the TECOM Group.
Janahi has played an instrumental role in establishing Dubai Science Park as the region’s leading community for scientific research and innovation, attracting more than 350 companies and strengthening partnerships among corporations, universities, and communities.
Janahi also serves as Chairing Member of the Pharmaceuticals and Medical Equipment Taskforce of the Dubai Industrial Strategy. In this capacity, he works with the Executive Council of Dubai to increase research and development investments, and enhance local pharmaceutical infrastructure and manufacturing capabilities.
Prior to his current position, Janahi held various roles from Sales Manager to Director at DuBiotech and EnPark, two free zones that have joined forces to now form Dubai Science Park. Early in his career, he worked as Commercial Manager for the UAE and Iran at Davidoff, the Swiss luxury goods brand, and as Business Analyst at DUBAL.
Marwan Abdulaziz Janahi holds a BBA in Marketing from the University of Texas at Arlington in the US. In addition, he successfully completed the INSEAD-UAE Consortium for Executive Development programme, the Cranfield General Management Programme at Cranfield University in the UK, and the Future Leaders Programme for UAE nationals.
Dr. Sawsan A. S. Al Madhi has more than 14 years progressive leadership skills and experience in strategy, operations and administration for the not-profit charitable sector. Currently working with one of the most reputable charities in the UAE as the Director General for Friends of Cancer Patients, Dr. Sawsan’s role is to supervise the continuing refinement and expansion of the organizational objectives which include: providing high quality services, organizing fundraising activities, developing, planning and executing nationwide awareness programs and campaigns through collaboration with a vast network of national and international, governmental and private sector organizations.
Dr. Al Madhi is an Internal Medicine specialist, Fellow of The Royal Society of Medicine (London), and a registered doctor with the General Medical Council in the United Kingdom. Her clinical and medical expertise is based on working at the Dubai Health Authority (Dubai- UAE) and at the Ministry of Health (Sharjah-UAE). She also holds a Master’s degree in Healthcare management from the Institute of Leadership of the Royal College of Surgeons of Ireland. Having medical, nonprofit and international expertise, Dr. Al Madhi strives to achieve excellence, sustainability, and attain results in the non-profit sector especially the non-profits working within health related matters and sectors.
MEMBERSHIPS & CONTRIBUTIONS
In addition, Dr. Al Madhi is an active member on a number of panels and boards including the Royal College of Surgeons of Ireland UAE chapter Alumina board, the Breast Cancer awareness program committee (Sharjah, MOH), the National Committee for Cancer Control (NICC,MOH-UAE), the Clinical Research Ethical Committee (Sharjah- UAE), NCD national committee - UAE, Government accelerator - UAE, The Gulf Federation For Cancer Control scientific committee representing UAE and Executive Committee for the Middle East Partnership for Women’s Health, Cancer Control and Research, Steering committee member, Cancer Advocacy Leader’s Alliance in Middle East & Africa (CALAMEA), Faculty member of the Institute of Cancer Policy - UK, to name a few.
Dr. Al Madhi is also a renowned public speaker in many areas including the future of non- profit, CSR and sustainability, gender balance, women and leadership. Dr. Al Madhi also focuses on women’s health and consntantly highlighting this topic in her frequent educational lectures, workshops, and panel discussions.
ACADEMICS & RESEARCH
Venturing into the Academic and Research platform Dr. Al Madhi is currently a visiting lecturer on the topics of “Healthcare management”, “Public Health”, “International health policy” ,”Health education and promotion” , “Healthcare process” , “ Health care systems “and “Patients care” in one of the most prestigious academic institutes in UAE the Canadian University in Dubai.
Dr. Al Madhi with her forward thinking, problem solving, creative and results oriented approach can propel organizations towards achieving goals and supporting its multifaceted needs in the philanthropy sector.
Working as a Regulatory affairs expert with hands - on experience of twelve years in regulatory affairs field in Egypt in international and local firms with strong focus on consumer care sector as well as medicinal products e ffective at establishing and implementing regulatory short - and long - range goals, objectives, policies to ensure well - run business. Working as a regulatory professional Since 2006 , with diversified experience, recognized for strong work ethic combined with commitment to excellence. Acknowledged in utilizing out - of - the - box techniques to develop new strategies and business
Vice President and Chief Operating Officer at Vantari Genetics, USA
Global Mergers & Acquisitions & New Products’ Launch Master
Started his career as a Urologist before joining Johnson & Johnson in 1996, where he assumed several leadership roles in Sales & Marketing, Strategy, Government Affairs and Market Access
Member of ISPOR (International Society for Pharmaco-economics and Outcomes Research) Board of Consultants for new medical technology & pharmaceuticals assessment
Main founder of MECOMED, the Middle Eastern chapter of the Trade Association of international MD&D manufacturers
Dr. Magdy Fahmy holds a Pharm. D. in pharmaceutical Science as well as an MBA in General Management. He benefits from over 25 years of pharmaceutical experience in key regional positions.
Dr. Magdy’s career and wealth of experience grew in an immeasurable manner during his 12 years tenure as Sales & Marketing Director at Julphar Gulf Pharmaceutical industries. He then took on the role of CEO of Planet Pharmacies before beginning his journey as CEO of LIFEPharma.
This is an individual who consistently demonstrates high levels of creativity and professionalism while excelling at people management. He possesses an excellent understanding of business dynamics and shows a strong business acumen. Dr. Magdy believes that motivation on personal level Is the best strategy to achieve the optimal results from each of his team members while he simultaneously maintains a macro-view of the business strategy and long term vision.
Dr. Magdy is an achiever by nature and is relentless when it comes to accomplishing business objectives.
“We, at LIFEPharma, are conscious of the current regional and global healthcare needs. We are equally attuned to the responsibilities that the resulting opportunities confer. Working to meet these needs, as we serve our patients, is at the heart of our mission for the coming years.”
A quote from Dr. Magdy Fahmy.
A Senior Executive Physician, Dr. Gul spent several years in healthcare business development and management for
- Clinic operation development, medical recruitment, business development and management
- International medical services (medical tourism, assistance, evacuation, repatriation)
- On-Site / remote medical services (occupational health, onshore – offshore clinic management)
Having had the opportunity to become affiliated with different countries and cultures, Dr. Gul holds significant experience in health, insurance, aviation sectors, mainly in the Middle East and North Africa region.
Dr. Gul is passionate for CSR & Sustainability and founder and Executive Director of CSR Middle East platform (2005) leading thousands of corporate members on their regional initiatives.
Dr. Gul is on the prestigious list of "2011 TOP 100 THOUGHT LEADERS in Europe and the Middle East”.
Joe Henein is a senior executive with an accomplished career extending over 30 years in the pharmaceutical industry, and covering many geographies including; USA (Global), Europe, and the Middle East/Africa. Joe holds a Pharm D Degree.
Joe joined NewBridge as President and CEO- a specialty pharma positioned to be first-in-class licensing only platform for innovative therapeutics, and bridge the access gap between innovation and patients by licensing innovative products from global pharmaceutical companies to Middle East and Africa Region.
Prior to that Joe worked in Big Pharma, mostly Wyeth Pharmaceuticals which is now a part of Pfizer. He assumed many roles of increased dimensions in the industry, most notably Vice President and Global Commercial Chair for number of therapeutic areas in Wyeth, like Infectious Diseases, and Women’s Health Care. He also assumed the role of VP & Regional Managing Director for Wyeth in MEA from 2005-2010.
Joe served in various Wyeth executive committees during his tenure as; Global Development Council, Global Development Strategy Board, and European Operation Council. On the industry level, he also served as the Vice Chair for the PhRMA MEA Committee and the Chair for the PhRMA MEA Ethics Review Board.
As Senior Business Development Manager, Administration Systems since 2004, Henrik has worked on promoting and enhancing West’s offering in devices for safety and reconstitution. Henrik joined West in 2001 as an Account Manager in the Nordic Region.
He holds a B.Sc. (econ) from the International Business College in Kolding, Denmark.
His Excellency Dr. Amin Hussain Al Amiri is the Asst. Undersecretary of Public Health Policy & Licensing Sector in UAE Ministry of Health & Prevention.
Dr. Al Amiri got his Ph.D. and Ms. C. in Medical Science in 2003 from Faculty of Medicine; Aberdeen University in Scotland; UK.
He is responsible for the following departments at MOHAP:
- Drug Dept.
- Empowerment & Health Compliance Dept.
- Organization, Licenses & Advertisement Dept.
- Public Health Policies Dept.
Roshel Jayasundera oversees the market access strategy consultancy practice at Axios International, a global healthcare access company with 20 years of specialized experience developing practical and sustainable solutions to patient access challenges in emerging markets and developing countries. She is also responsible for global client relationship management across Africa, Asia, Latin America, Europe and the Middle East. Specialized in pharmaceutical and medical capacity building, technical process design, regulatory affairs and best practice standards, Roshel has developed business improvement solutions for governments, international private and public companies and start-ups across Europe, the Middle East and Asia. Roshel holds a Bachelor of Science (BSc) in Medical Biotechnology from the University of L’Aquila (Italy) and is currently completing her Global MBA from Alliance Manchester Business School (UK). She is also a certified ISO 9001:2008 Lead Auditor.
Yasin is currently the Manager of the Technical Office and Manager of the Pharmaceutical Supply Department at Central Administration of Pharmaceutical Affairs (CAPA), Egyptian Drug Authority. Yasin was the rapporteur of the Drug Shortage Committee in 2013, executive member of the public pharmaceutical supply chain reform program from 2012 till 2014. He is the project manager of National "Pharmaceutical Track and Trace" project in Egypt. He led a joint WHO-World Bank medicines availability survey project in 2013 in the Egyptian market. He represented different Egyptian delegations across borders and media and press representative for pharmaceutical sector.
Yasin has various technical and administrative experiences in variety of disciplines including policy analysis, operations management, medicines regulations, pharmacoeconomics, medicine supply chain management, and pharmaceutical manufacturing quality. He was a Judge during the ISPOR International meeting in Washington D.C., and "Value in Health" Reviewer for the ISPOR 19th European Congress in Vienna and ISPOR 6th Latin American Conference.
Yasin got his bachelors in Pharmacy from Ain Shams University in 2006, then Master's in Business Administration (MBA) from the University of Portland, USA in 2012. In 2016, he got a Master's in Public Policy (MPP) from the American University in Cairo in addition to a postgraduate certificate in "Pharmaceutical Policy Analysis" from University of Utrecht.
Sophie is the Co-founder and CEO of Nabta Health (www.nabtahealth.com), the first dedicated platform for women's health in the MENA region.
Prior to co-founding Nabta, Sophie launched several other companies and products in the HealthTech space, including myZindagi, now the No. 1 doctor-booking portal in Pakistan.
Sophie’s lifetime ambition is to empower women from all backgrounds, cultures and means to effectively manage their health. To this end, Sophie is patron of Kings College London MedTech Society and has worked in an advisory capacity with multiple healthcare organisations including MedShr, Diabetes.co.uk and It Gets Brighter.
Sophie read History at the University of Cambridge.